Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-29
2008-07-29
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S237000, C544S238000, C514S252060
Reexamination Certificate
active
07405215
ABSTRACT:
The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
REFERENCES:
patent: 3590047 (1971-06-01), Shen et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 6114532 (2000-09-01), Ries et al.
patent: 6121308 (2000-09-01), Hauel et al.
patent: 6365584 (2002-04-01), Anderskewitz et al.
patent: 2006/0106081 (2006-05-01), Bennani et al.
patent: 62-024244 (1987-02-01), None
patent: 2000-095767 (2000-04-01), None
patent: 2000-143635 (2000-05-01), None
patent: WO 97/10219 (1997-03-01), None
patent: WO 02/060438 (2002-08-01), None
patent: WO 03/066046 (2003-08-01), None
patent: WO 03/066047 (2003-08-01), None
patent: WO 03/101961 (2003-12-01), None
patent: WO 03/101981 (2003-12-01), None
patent: WO 2004/007451 (2004-01-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Chalmers (TiPS vol. 17, pp. 162-172 Apr. 1996).
Böhm, E., et al., “11-Dehydro-thromboxane B2, a Stable Thromboxane Metabolite, Is a Full Agonist of Chemoattractant Receptor-homologous Molecule Expressed on TH2 Cells (CRTH2) in Human Eosinophils and Basophils,”J. Biol. Chem. 279:7663-7670, The American Society for Biochemistry and Molecular Biology, Inc. (Feb. 2004).
Boie, Y., et al., “Molecular Cloning and Characterization of the Human Prostanoid DP Receptor,”J. Biol. Chem. 270:18910-18916, The American Society for Biochemistry and Molecular Biology, Inc. (1995).
Fujitani, J., et al., “Pronounced Eosinophilic Lung Inflammation and Th2 Cytokine Release in Human Lipocalin-Type Prostaglandin D Synthase Transgenic Mice,”J. Immunol. 168:443-449, The American Association of Immunologists (2002).
Hirai, H., et al., “Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor CRTH2,”J. Exp. Med. 193:255-261, The Rockefeller University Press (2001).
Liu, M.C., et al., “Evidence for Elevated Levels of Histamine, Prostaglandin D2,and Other Bronchoconstricting Prostaglandins in the Airways of Subjects with Mild Asthma,”Am. Rev. Respir. Dis. 142:126-132, American Lung Association (1990).
Nagata, K., et al., “Selective Expression of a Novel Surface Molecule by Human Th2 Cells In Vivo,”J. Immunol. 162:1278-1286, The American Association of Immunologists (1999).
International Search Report for PCT Application No. PCT/US2005/034028 dated Mar. 23, 2006.
International Search Report for corresponding PCT Application No. PCT/US2005/034029 dated Apr. 27, 2007.
Bennani Youssef L.
Gleason Elizabeth Ann
Robarge Michael Joseph
Tumey Lawrence Nathan
Finnegan Henderson Farabow Garrett & Dunner LLP
Habte Kahsay T
Wyeth
LandOfFree
Indole acetic acids exhibiting CRTH2 receptor antagonism and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole acetic acids exhibiting CRTH2 receptor antagonism and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole acetic acids exhibiting CRTH2 receptor antagonism and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2812984